+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Regulation of the C3 Production by Gamma Interferon from Peripheral Blood T Cells in Patients with Membranoproliferative Glomerulonephritis and Poststreptococcal Acute Glomerulonephritis

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          This study assessed the regulatory role of peripheral blood T cells in the C3 production in patients with poststreptococcal glomerulonephritis and membranoproliferative glomerulonephritis. Peripheral blood T cells from patients at various stages of disease were cultured and the supernatants tested for gamma interferon (IFN-γ) content and the capacity to stimulate C3 production by HuH-7 cells. Supernatants from patients with membranoproliferative glomerulonephritis and from convalescent patients with poststreptococcal glomerulonephritis significantly stimulated the C3 production; the degree of stimulation correlated with the IFN-γ content of the supernatants. Similar results were obtained using recombinant IFN-γ. In both cases, the effect was blocked by the addition of anti-IFN-γ monoclonal antibody to the cultures. Interleukin 2 and interleukin 6 levels in supernatants from T cell cultures of patients and controls were essentially the same. In summary, IFN-γ plays a regulatory role in C3 production by human hepatoma cell lines.

          Related collections

          Author and article information

          S. Karger AG
          18 December 2008
          : 72
          : 4
          : 623-628
          Departments of Pediatrics, aKyorin University School of Medicine and bMitusi Memorial Hospital, Tokyo, Departments of Immunology, cNational Children’s Medical Research Center, Tokyo, and dMiyagi Cancer Center Research Institute, Miyagi, Japan
          188950 Nephron 1996;72:623–628
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper

          Cardiovascular Medicine, Nephrology

          C3 production, Gamma interferon, Hepatoma cells


          Comment on this article